Cardiac Science Announces Record Fourth Quarter Revenue of $1.48 Million; $4.24 Million Revenue and 734 Powerheart Hospital Bedside Defibrillator-Monitors Sold in 2000.

Business Editors & Health/Medical Writers

IRVINE, Calif.--(BW HealthWire)--Jan. 17, 2001

Cardiac Science Inc. (Nasdaq:DFIB), the developer of the only hospital monitor that provides life-saving defibrillation within seconds and without human intervention, today announced that it sold 251 Powerheart(R) defibrillator-monitors for the three months ended Dec. 31, 2000 resulting in record quarterly sales of $1,481,000.

This performance represents a 1,338 percent increase in revenue compared to the quarter ended Dec. 31, 1999.

Revenue for the year 2000 totaled $4,240,000 and compares to revenue of $103,000 for the year 1999. Powerheart represents the first commercial product to utilize Cardiac Science's proprietary RHYTHMx ECD(TM) tachyarrhythmia detection and defibrillation technology and related disposable defibrillation electrodes. A total of 734 devices have been sold this year.

"Our year-end sales reflect increasing adoption of our Powerheart technology by hospital customers in the United States and around the world. We anticipate strong revenue growth in 2001 from continued sales of Powerheart, new business partnerships, and the combination of our proprietary automatic defibrillation technology with bedside, portable and ambulatory patient monitors and external defibrillators. In addition, anticipated new regulatory clearances for our products will expand our market opportunities outside the hospital," said Michael Gioffredi, vice president, sales and marketing. "We now have confirmed reports of nine patient lives saved in the last few months and we are encouraged by feedback from both physicians and nurses to our new life-saving technology."

During the second half of 2000, Powerheart defibrillator-monitors were sold to numerous hospitals in the United States including Valley Lutheran Hospital, Mesa, Arizona; Cedars-Sinai Medical Center, Los Angeles; Santa Teresita Hospital, Duarte, California; Rush-Presbyterian St. Luke's Medical Center, Chicago; Anaheim and Santa Ana Western Medical Centers in California and Murphy Medical Center in North Carolina.

Powerhearts were sold in 13 other countries around the world including European hospitals in Italy, Greece, Spain, Portugal, Poland, Czech Republic and Hungary. Hospitals in Latin American countries include Mexico, Venezuela, Argentina and Brazil. Powerheart sales in Asia include hospital customers in Korea and China.

About Cardiac Science

Cardiac Science develops, manufactures and markets life-saving external cardiac defibrillator devices and proprietary software that monitors and automatically treats patients who suffer life-threatening heart rhythms.

The company's core proprietary tachyarrhythmia detection, defibrillation and electrode technology platform has multiple applications, including use in external and wearable defibrillators and with standard patient monitors widely used in hospitals and surgery centers throughout the world. The growth of the company's installed base will provide a recurring revenue stream from the sale of its proprietary disposable defibrillator electrodes.

Cardiac Science's global sales network consists of prominent distributors encompassing Asia, the Middle East, Europe, South America and North America. In addition, the company has a distribution agreement with Medtronic Physio-Control, a division of Medtronic, Inc., the worldwide market leader in external defibrillator products, to distribute the Powerheart in the United States, Canada, and nine European countries. For more information on Cardiac Science, visit its Internet site at www.cardiacscience.com.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Such forward looking statements include, but are not limited to: the life-saving potential of Cardiac Science's technology, its ability to accelerate the adoption rate of the company's technology, anticipated revenue growth and new regulatory clearances, generate significant recurring revenue, potentially save thousands of lives, develop new products, improve patient-care and prevent complications caused by delayed defibrillation. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors known and unknown that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. These factors include, without limitation, market acceptance of Cardiac Science's products, future economic, regulatory, competitive, and market conditions and future business decisions. Information on these and other factors is detailed in the company's Form 10-K for the year ending Dec. 31, 1999 and other documents filed with the Securities and Exchange Commission.